Glofitamab-Gxbm

The addition of glofitamab-gxbm to gemcitabine and oxaliplatin improved OS among patients with relapsed or refractory diffuse large B-cell lymphoma compared with rituximab, gemcitabine and oxaliplatin, according to the agent’s manufacturer.

More than 20% of reported cases of adverse events following bispecific T-cell engager therapies involved a cardiovascular event, findings reported in Journal for ImmunoTherapy of Cancer showed.

In this video, Tycel Phillips, MD, discusses treatment options available to patients with DLBCL.

In this video, Stephen M. Ansell, MD, PhD, discusses research presented at ASH Annual Meeting and Exposition on circulating tumor DNA.

In this video, Stephen M. Ansell, MD, PhD, discusses primary analysis results from the phase 3 Sympatico study.

In this video, Brian T. Hill, MD, PhD, discusses important research on bispecific antibodies for the treatment of lymphoma presented at ASH Annual Meeting and Exhibition.

Healio spoke with Joshua Brody, MD, about unmet needs and distinct challenges, as well as the treatment landscape in diffuse large B-cell lymphoma.